NCT03546426View on ClinicalTrials.gov

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

January 31, 2027

Study Completion Date

September 30, 2028

Conditions
Mesothelioma, MalignantPD-L1 NegativeAdvanced CancerProgressive Disease
Interventions
DRUG

Pembrolizumab

200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years

BIOLOGICAL

Autologous dendritic cells

Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses

DRUG

Interleukin-2

3 MU s.c. from day +2 to day +6 after each DC administration

Trial Locations (1)

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER